

Veröffentlichungen Urologie und Medizingeschichte

(*in Pubmed gelisteten Journalen, ** in Reihen- und Buchveröffentlichungen)

Nummer	Publikationen (Autoren, Titel, Journal)	Impact-Faktor	Autorenschaft
211*	Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W , van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Bussani R, Allory Y, van Rhijn BWG. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 2023 Feb 6. doi: 10.1111/bju.15984. Epub ahead of print. PMID: 36748180.	5,969	Co-Autor
210*	Kotlyar MJ, Krebs M, Solimando AG, Marquardt A, Burger M, Kübler H, Bargou R, Kneitz S, Otto W , Breyer J, Vergho DC, Kneitz B, Kalogirou C. Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava. Cancers (Basel). 2023 Mar 26;15(7):1981. doi: 10.3390/cancers15071981. PMID: 37046643; PMCID: PMC10093292.	6,575	Co-Autor
209*	Mayr R, Eckstein M, Wirtz RM, Santiago-Walker A, Baig M, Sundaram R, Carcione JC, Stoehr R, Hartmann A, Bolenz C, Burger M, Otto W , Erben P, Breyer J. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. Eur Urol. 2022 Jun;81(6):606-614. doi: 10.1016/j.eururo.2022.02.028. Epub 2022 Mar 26. PMID: 35351346.	24,344	Co-Autor
208*	Mertens LS, Claps F, Mayr R, Hodgson A, Shariat SF, Hippe K, Neuzillet Y, Sanders J, Burger M, Pouessel D, Otto W , van der Kwast TH, Lotan Y, Allory Y, Downes MR, van Rhijn BWG. The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. Int J Surg Pathol. 2022 Apr 24:10668969221095173. doi: 10.1177/10668969221095173. Epub ahead of print. PMID: 35466737.	1,358	Co-Autor
207*	Erlmeier F, Bruecher B, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W , Burger M, Schrader AJ, Hartmann A, Mondorf Y, Ivanyi P, Mikuteit M, Steffens S; German Network Of Kidney Cancer. cMET: a prognostic marker in papillary renal cell carcinoma? Hum Pathol. 2022 Mar;121:1-10. doi: 10.1016/j.humpath.2021.12.007. Epub 2022 Jan 6. PMID: 34998840	3,526	Co-Autor
206*	Mondorf Y, Mikuteit M, Ivanyi P, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief CG, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W , Burger M, Schrader AJ, Hartmann A, Steffens S, Erlmeier F. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. Urol Int. 2022;106(11):1168-1176. doi: 10.1159/000525016. Epub 2022 Jun 2. PMID: 35654002.	2,089	Co-Autor

205*	Zschäbitz S, Mikuteit M, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W , Burger M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S. Expression of nectin-4 in papillary renal cell carcinoma. Discov Oncol. 2022 Sep 22;13(1):90. doi: 10.1007/s12672-022-00558-2. PMID: 36136143; PMCID: PMC9500133.	4,67	Co-Autor
204*	Mikuteit M, Zschäbitz S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W , Burger M, Schrader AJ, Hartmann A, Steffens S, Erlmeier F. The prognostic impact of Claudin 6 in papillary renal cell carcinoma. Pathol Res Pract. 2022 Mar;231:153802. doi: 10.1016/j.prp.2022.153802. Epub 2022 Feb 11. PMID: 35180650.	3,309	Co-Autor
203*	Zschäbitz S, Erlmeier F, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W , Burger M, Schrader AJ, Mondorf Y, Hartmann A, Ivanyi P, Steffens S. Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort. J Cancer. 2022 Mar 14;13(6):1706-1712. doi: 10.7150/jca.63509. PMID: 35399715; PMCID: PMC8990413.	4,478	Co-Autor
202*	Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W , Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM, van Rhijn BWG. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urol Oncol. 2021 Dec 11:S1078-1439(21)00475-0. doi: 10.1016/j.urolonc.2021.10.010.	2,954	Co-Autor
201*	Otto W , Wieland WF. Wechselwirkungen von radikaler Prostatovesikulektomie und Diagnostik des Prostatakarzinoms: Eine medizinhistorische Bestandsaufnahme anlässlich 20 Jahre robotisch assistierter Therapie [Interactions between radical prostatovesiculectomy and diagnosis of prostate cancer: A medical-historical inventory on the occasion of 20 years of robot-assisted treatment]. Urologe A. 2021 Aug;60(8):1039-1050. German. doi: 10.1007/s00120-020-01389-1.	0,803	Erst-Autor
200*	Spachmann PJ, Rupp C, Fritsche HM, Denzinger S, Burger M, Breyer J, Otto W , Schnabel MJ. Impact of Male Patient Information on Quality of Urine Examination (PIQUE Study). Urol Int. 2021 Aug 26:1-5. doi: 10.1159/000517783.	1,86	Co-Autor
199*	Promm M, Otto W , Weber F, Götz S, Burger M, Müller K, Rubenwolf P, Neuhuber W, Roesch WH. Expression of Low Affinity Nerve Growth Factor Receptor p75 in Classic Bladder Exstrophy. Front Pediatr. 2021 Feb 22;9:634343. doi: 10.3389/fped.2021.634343.	3,569	Co-Autor

198*	Sikic D, Taubert H, Breyer J, Eckstein M, Weyerer V, Keck B, Kubon J, Otto W , Worst TS, Kriegmair MC, Erben P, Hartmann A, Wullich B, Wirtz RM, Wach S. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. Cancer Manag Res. 2021 Aug 20;13:6567-6578. doi: 10.2147/CMAR.S318893.	3,46	Co-Autor
197*	Eckstein M, Kimmel C, Bruendl J, Weber F, Denzinger S, Gierth M, Burger M, Hartmann A, Otto W , Breyer J. Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer. Sci Rep. 2021 Sep 9;11(1):17981. doi: 10.1038/s41598-021-97500-3.	4,996	Co-Autor
196*	Manseck AS, Otto W , Schnabel M, Denzinger S, Burger M, Spachmann PJ. Geriatric Patients and Symptomatic Urinary Tract Infections: Analysis of Bacterial Range and Resistance Rates at a 3rd Level of Care Hospital in Germany. Urol Int. 2021 Jun 25:1-6. doi: 10.1159/000516677.	1,86	Co-Autor
195	Breyer J, Otto W . Immuntherapie des fortgeschrittenen und metastasierten Urothelkarzinoms der Harnblase - ein neuer Goldstandard? Journal Onkologie 10/2020	-	Co-Autor
194	Otto W , Breyer J, Burger M. Der aktuelle Blick auf das nicht muskelinvasive Harnblasenkarzinom. Journal Onkologie 10/2020	-	Erst-Autor
193**	Otto W . Therapietabellen Uroonkologie. mgo-Fachverlage, München, 2020	-	Einzel-Autor
192**	Otto W . Therapie des metastasierten hormonsensitiven Prostatakarzinoms. In: Jocham D, Miller K, Burger M, Schrader M: Praxis der Urologie, 4. Auflage, Thieme, Stuttgart, 2020	-	Einzel-Autor
191	Reiß J, Rosenhammer B, Otto W , Burger M, Bründl J. Fokale Therapie des Prostatakarzinoms Journal Onkologie 8/2020	-	Co-Autor
190	Schnabel MJ, Burger M, Otto W . Operative Therapie des metastasierten Nierenzellkarzinoms Journal Onkologie 8/2020	-	Senior-Autor
189*	Erlmeier F, Steffens S, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W , Burger M, Schrader AJ, Hartmann A, Ivanyi P; (German Network Of Kidney Cancer). Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study Clin Genitourin Cancer. 2021 Feb;19(1):53-59.e1. doi: 10.1016/j.clgc.2020.07.002. Epub 2020 Jul 9.	2,695	Co-Autor
188*	van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, van der Heijden MS, Jewett MAS, Marquez M, Stoehr R, Zlotta AR, Eckstein M, Soorobjally Y, Roshani H, Burger M, Otto W , Radvanyi F, Sirab N, Pouessel D, Wullich B, van der Kwast TH, Malats N, Hartmann A, Allory Y, Zuiverloon TCM. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? Eur Urol 2020 Jul 15;S0302-2838(20)30531-5. Epub 23.06.2020	17,947	Co-Autor

187*	Sikic D, Eckstein M, Wirtz RM, Jarczyk J, Worst TS, Porubsky S, Keck B, Kunath F, Weyerer V, Breyer J, Otto W , Rinaldetti S, Bolenz C, Hartmann A, Wullich B, Erben P. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy J Clin Med. 2020 Apr 2;9(4):994. Epub 10.04.2020	6,78	Co-Autor
186**	Otto W , Hanika H, Behr M. Urogenitale Krankheitsbilder. In: Behr M, Fanghänel J, Proff P, Reichert TE (Hrsg.): Risikopatienten in der Zahnarztpraxis. Behandlung von Patienten verschiedener Krankheitsbilder und Therapiekonzepte der Medizin. 2. Auflage, Deutscher Ärzteverlag, Köln, 2020	-	Erst-Autor
185	Wieland WF, Burger M, Denzinger S, Otto W , Pavlov VN. Radical Prostatectomy: from Open Surgery towards Robotic Laparoscopy Creative Surgery and Oncology. 2020; 10(2)	-	Co-Autor
184*	Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C, Wullweber A, Lange F, Erben P, Stoehr R, Bertz S, Geppert CI, Fuhrich N, Taubert H, Wach S, Breyer J, Otto W , Burger M, Bolenz C, Keck B, Wullich B, Hartmann A, Sikic D; BRIDGE Consortium e.V., Mannheim, Germany Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy J Immunother Cancer. 2020 May;8(1):e000162. Epub 15.12.2019	9,913	Co-Autor
183	Spachmann PJ, Wehding F, Eichfelder K, Breyer J, Gierth M, Burger M, Otto W . Urotheliales CIS der Harnblase: eine Analyse zur Qualität der PDD an einem universitären Einzelzentrum. UroForum 12/2019	-	Senior-Autor
182*	Spachmann PJ, Azzolina V, Weber F, Evert M, Eckstein M, Denzinger S, Burger M, Otto W , Breyer J. Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC) Pathol Oncol Res. 2020 Jul;26(3):1625-1632. Epub 10.09.2020	2,433	Co-Autor
181	Spachmann PJ, Wehding F, Eichfelder K, Breyer J, Gierth M, Denzinger S, Burger M, Otto W . Diagnostik des urothelialen Carcinoma in situ der Harnblase – eine Analyse zur Qualität der photodynamischen Diagnostik an einem universitären Einzelzentrum Urologische Nachrichten 9/2019	-	Senior-Autor
180*	Hutterer GC, Posch F, Buser L, Zigeuner R, Morshäuser L, Otto W , Wild PJ, Burger M, May M, Pichler M, Brookman-May SD. BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study. Urol Oncol. 2019 Jul;37(7):510-518. Epub 03.05.2019	2,882	Co-Autor
179*	Pfannstiel C, Strissel P, Chiappinelli K, Sikic D, Wach S, Wirtz R, Wullweber A, Taubert H, Breyer J, Otto W , Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert C, Weyerer V, Stöhr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M. Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes Cancer Immunol Res. 2019 Jun;7(6):923-938. Epub 15.04.2019	8,07	Co-Autor
178*	Spachmann PJ, Breyer J, Kalogirou C, Lausenmeyer EM, Weber F, Evert M, Prohaska S, Denzinger S, Burger M, Kübler H, Otto W , Vergho D. Impact of E-cadherin and β -Catenin as prognostic factor in renal cell carcinoma with tumor thrombus of the Vena cava Urol Int. 2019;102(4):413-420. Epub 07.03.2020	1,401	Co-Autor

177*	Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W , Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B. Androgen receptor mRNA expression in urothelial carcinoma of the bladder: A retrospective analysis of two independent cohorts Transl Oncol. 2019 Apr;12(4):661-668. Epub 02.03.2019	3,138	Co-Autor
176*	Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W , Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer. 2019 Jan;106:234-243. Epub 05.12.2018	7,275	Co-Autor
175*	Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W , Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Arch. 2019 Feb;474(2):209-217. Epub 28.11.2018	2,906	Co-Autor
174**	Otto W , Burger M, Breyer J. Early-Invasive Urothelial Bladder Carcinoma and Instillation Treatment of Non Muscle-Invasive Bladder Cancer. In: Burger M, Meerseburger A: Urologic Oncology. Springer, New York, 2018	-	Erst-Autor
173*	Lausenmeyer EM, Braun K, Breyer J, Gierth M, Denzinger S, Burger M, Voelker HU, Otto W . Strong Expression of Cancer-testis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer. Urol Int. 2019;102(1):77-82. Epub 01.11.2018	1,401	Senior-Autor
172*	Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W , Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Proubsky S, Hartmann A, Erben P. mRNA-Expression of <i>KRT5</i> and <i>KRT20</i> Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. Int J Mol Sci. 2018 Oct 30;19(11). Epub 30.10.2018	3,687	Co-Autor
171*	Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W , Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018 Sep 26;8(1):14383. Epub 26.09.2018	4,122	Co-Autor
170*	Sterzik A, Solyanik O, Eichelberg C, Jost M, Graser A, Lausenmeyer EM, Otto W , Waidelich R, Stief CG, Burger M, May M, Brookman-May SD. Improved prediction of nephron-sparing surgery versus radical nephrectomy by the optimized R.E.N.A.L. (optR.E.N.A.L.) score in patients undergoing surgery for renal masses. Minerva Urol Nefrol. 2018 Sep 24. doi: 10.23736/S0393-2249.18.03134-X. Epub 24.09.2018	1,449	Co-Autor
169*	Bründl J, Nepl C, Hommer T, Otto W , Breyer J, Brookman-May S, Weber F, Burger M, May M, Eichelberg C. [Role of p16(INK4A) in detection of human papillomavirus DNA and stratification of cancer-specific mortality on the basis of long term follow-up data of 34 patients with invasive penile cancer]. German Aktuelle Urol. 2018 Sep 18. doi: 10.1055/a-0664-0316. Epub 18.09.2018	0,235	Co-Autor

168*	Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W . FOX M1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. BJU Int. 2019 Jan;123(1):187-196. Epub 09.09.2018	4,688	Senior-Autor
167*	Otto W . [Two syphilidologists and their most popular leisure activity: Walther Pick (1874-1932) and Hermann Schlesinger (1866-1934) as knights of Schlaraffia Vindobona]. German Urologe A. 2018 Sep 3. doi: 10.1007/s00120-018-0768-2 Epub 03.09.2018	0,437	Erst-Autor
166*	Bründl J, Wallinger S, Breyer J, Weber F, Evert M, Georgopoulos NT, Rosenhammer B, Burger M, Otto W , Rubenwolf P. Expression, localisation and potential significance of aquaporins in benign and malignant human prostate tissue. BMC Urol. 2018 Sep 3;18(1):75. doi: 10.1186/s12894-018-0391-y. Epub 03.09.2018	1,792	Co-Autor
165*	Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Höfler H, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W , Burger M, Haferkamp A, Geppert CI, Stöhr C, Hartmann A; German Network Of Kidney Cancer. High proliferation rate and TNM-stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Hum Pathol. 2019 Jan;83:212-223. Epub 17.08.2018	3,125	Co-Autor
164*	Otto W . Stage T1 bladder cancer: historic background and latest tracks for its demystification. Transl Androl Urol. 2018 Aug;7(4):760-763. Epub 13.06.2018	2,113	Einzel-Autor
163*	Fransen van de Putte EE, Otto W , Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG. Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urol Oncol. 2018 Aug;36(8):361. Epub 05.06.2018	3,397	Co-Autor
162*	van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W , Burger M, Hartmann A, van Rhijn BWG. The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer. BJU Int. 2018 Dec;122(6):978-985. Epub 27.04.2018	4,688	Co-Autor
161*	Eckstein M, Wirtz RM, Pfannstiel C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W , Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget. 2018 Feb 19;9(19):15001-15014. Epub 13.03.2018	5,168	Co-Autor
160*	Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W , Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P. Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer. Transl Oncol. 2018 Apr;11(2):467-476. Epub 23.02.2018	3,071	Co-Autor

159*	Otto W , van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A. Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer. Int J Urol. 2018 May;25(5):442-449. Epub 22.02.2018	1,941	Erst-Autor
158*	Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W . High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. Epub 02.02.2018	2,539	Senior-Autor
157*	Baker SC, Arlt VM, Indra R, Joel M, Stiborová M, Eardley I, Ahmad N, Otto W , Burger M, Rubenwolf P, Phillips DH, Southgate J. Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolizing activity of "luminal" muscle-invasive bladder cancers. Mol Carcinog. 2018 May;57(5):606-618. Epub 01.02.2018	5,072	Co-Autor
156*	Morshaeuser L, May M, Burger M, Otto W , Hutterer GC, Pichler M, Klatte T, Wild P, Buser L, Brookman-May S. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models. Urol Oncol. 2018 Mar;36(3):94.e15-94.e21. Epub 06.12.2017	3,397	Co-Autor
155*	Breyer J, Wirtz RM, Otto W , Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother. 2018 Mar;67(3):403-412. Epub 17.11.2017	4,225	Co-Autor
154*	Breyer J, Wirtz RM, Otto W , Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget. 2017 Jun 28;8(40):67684-67695. Epub 17.09.2017	5,168	Co-Autor
153**	Otto W , Burger M. Die Therapieentscheidung – Sie entscheiden mit. In: Akoa G, Burger M, Otto W (Hrgs.): Prostatakrebs. Therapiebegleiter für Paare. TRIAS, Stuttgart, 2017	-	Erst-Autor
152**	Otto W , Burger M. Radikale Prostatektomie und andere operative Behandlungsmethoden des Prostatakarzinoms. In: Akoa G, Burger M, Otto W (Hrgs.): Prostatakrebs. Therapiebegleiter für Paare. TRIAS, Stuttgart, 2017	-	Erst-Autor
151**	Otto W . Antihormonale Therapie beim hormonempfindlichen metastasierten Prostatakarzinom. In: Akoa G, Burger M, Otto W (Hrgs.): Prostatakrebs. Therapiebegleiter für Paare. TRIAS, Stuttgart, 2017	-	Einzel-Autor
150	Breyer J, Otto W . Immuntherapie des fortgeschrittenen und metastasierten Urothelkarzinoms der Harnblase – ein neuer Goldstandard? Journal Onkologie 8/2017	-	Senior-Autor
149*	Breyer J, Shalekenov S, Aziz A, van Rhijn BWG, Bründl J, Lausenmeyer E, Schäfer J, Denzinger S, Giedl C, Burger M, Hartmann A, Evert M, Otto W . Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer. Bladder Cancer. 2017 Jul 27;3(3):173-180. Epub 31.05.2017	3,16	Senior-Autor

148*	Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W , Bolenz C, Hartmann A, Erben P. FOX M1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget. 2017 Jul 18;8(29):47595-47606. Epub 24.04.2017	5,168	Co-Autor
147*	Breyer J, Otto W , Lausenmeyer EM, Denzinger S, Schwientek AK, Ochs L, Mayr R, Gierth M, Bründl J, Burger M, Evert M, Fritsche HM, Eichelberg C. [Clinical and pathological prognostic factors for the long-term survival of patients with pT1 renal cell carcinoma]. German Aktuelle Urol. 2017 May;48(3):230-237. Epub 19.04.2017	0,437	Co-Autor
146*	Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W . High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Transl Oncol. 2017 Jun;10(3):340-345. Epub 22.03.2017	3,071	Senior-Autor
145*	Breyer J, Otto W , Burger M, Hartmann A, Rubenwolf PC. Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading? Bladder Cancer. 2017 Jan 27;3(1):31-34. Epub 27.01.2017	3,16	Co-Autor
144	Otto W , Burger M, Stenzl A, Gakis G. CME-Artikel Von Asymptomatik bis Zystektomie: 10 Fragen und Antworten zum frühinvasiven Urothelkarzinom der Harnblase Onkologie heute 1/2017	-	
143*	Breyer J, Wirtz RM, Otto W , Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. 2017 Mar;470(3):267-274 Epub 10.01.2017	2,848	Co-Autor
142*	Otto W , Breyer J, Herdegen S, Eder F, Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW, Burger M, Hartmann A. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. Int Urol Nephrol. 2017 Mar;49(3):431-437. Epub 29.12.2016	1,692	Erst-Autor
141*	Breyer J, Otto W , Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium. ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ. Urol Int. 2017;98(3):282-289. Epub 17.12.2016	1,508	Co-Autor
140*	Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W . ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Arch. 2016 Nov;469(5):547-552. Epub 11.09.2016	2,848	Senior-Autor
139*	Breyer J, Otto W , Hartmann A, Bumès B, Bründl J, Gierth M, Bertz S, Denzinger S, Burger M, Lausenmeyer EM. [Anamnesis, Pathological Assessment, Therapeutic Features and Course of Disease: Retrospective Study on Clinical-Based Factors for Prediction of Cancer-Specific Survival of 378 Patients with Stage pT1 Urothelial Bladder Carcinoma]. German Aktuelle Urol. 2015 May;46(3):221-6. Epub 12.06.2015	0,215	Co-Autor

138*	Breyer J, Denzinger S, Hartmann A, Otto W . Downregulation of Checkpoint Protein Kinase 2 in the Urothelium of Healthy Male Tobacco Smokers. Urol Int. 2016;97(4):480-481. Epub 02.06.2016	1,611	Senior-Autor
137*	Otto W . [More than just "stones": On the history of urology in Regensburg]. Urologe A. 2016 Jul;55(7):974-80. Epub 20.05.2016	0,289	Erst-Autor
136*	Breyer J, Burger M, Otto W . Immunotherapy in urothelial carcinoma: fade or future standard? Transl Androl Urol. 2016 Oct;5(5):662-667. Epub 06.04.2016	-	Senior-Autor
135	Otto W , Schultheiss D. CME-Artikel Entwicklungslinien der Urologie, Teil I: Altertum bis Aufklärung Urologie Scan 3/2016	-	Erst-Autor
134	Otto W . Videoeditorial 1/2016 Urologie Scan 1/2016	-	Einzel-Autor
133	Otto W , Burger M, Rubenwolf P. Aquaporin 3 in der Urologie Journal Onkologie 9/2015	-	Erst-Autor
132*	Breyer J, Gierth M, Shalekenov S, Aziz A, Schäfer J, Burger M, Denzinger S, Hofstädter F, Giedl C, Otto W . Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. World J Urol. 2016 May;34(5):709-16. Epub 22.09.2015	2,743	Senior-Autor
131	Otto W , Breyer J, Denzinger S, Burger M. Fluoreszenzdiagnostik des Harnblasenkarzinoms – Klinische Etablierung einer vielversprechenden Methode und ihre Limitationen Journal Onkologie 8/2015	-	Erst-Autor
130	Otto W , Breyer J. Chemotherapie fortgeschrittener Keimzelltumoren des Hodens Journal Onkologie 6/2015	-	Erst-Autor
129	Otto W , Lausenmeyer EM. Aktuelle Diagnostik und Therapie des Peniskarzinoms Journal Onkologie 6/2015	-	Erst-Autor
128*	May M, Brookman-May S, Burger M, Koch S, Otto W , Bründl J, Albrecht K, Denzinger S. A switch from epithelial to mesenchymal properties correlates with lymphovascular invasion in squamous cell carcinoma of the penis. Pathol Res Pract. 2015 Sep;211(9):641-5. Epub 28.05.2015	1,388	Co-Autor
127*	Rubenwolf P, Thomas C, Denzinger S, Hartmann A, Burger M, Georgopoulos NT, Otto W . Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer. World J Urol. 2015 Dec;33(12):1959-64. Epub 05.05.2015	2,397	Senior-Autor
126*	Gierth M, Mayr R, Aziz A, Krieger S, Wullich B, Pycha A, Lodde M, Salvadori U, Bründl J, Fritsche HM, Hofstädter F, Pawlik MT, Otto W , May M, Burger M, Denzinger S. Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy. J Cancer Res Clin Oncol. 2015 Oct;141(10):1819-26. Epub 02.04.2015	3,141	Co-Autor
125*	Gakis G, Stenzl A, Horn T, Gschwend JE, Otto W , Burger M. [Non-muscle-invasive high-grade bladder cancer]. German Urologe A. 2015 Apr;54(4):491-8. Epub 13.03.2015	0,331	Co-Autor

124	Breyer J, Otto W . Chemotherapie beim muskelinvasiven Harnblasenkarzinom – neoadjuvant, adjuvant oder palliativ? Journal Onkologie 3/2015	-	Senior-Autor
123	Lausenmeyer EM, Otto W . Adjuvante Strahlentherapie des Prostatakarzinoms nach radikaler Prostatektomie Journal Onkologie 10/2014	-	Senior-Autor
122*	Breyer J, Denzinger S, Otto W , Bründl J, Gierth M, Fritsche HM, Rößler W, Wieland WF, Giedl C, Hofstädter F, Rubenwolf P, Burger M, Aziz A. Outcome of Patients with Pathological Tumor Stage T3 Urothelial Carcinoma of the Bladder following Radical Cystectomy in a Single-Center Series with 116 Patients. Urol Int. 2014; 93(3):311-9. Epub 04.09.2014	1,426	Co-Autor
121*	Mayr R, May M, Burger M, Martini T, Pycha A, Dechet C, Lodde M, Comploj E, Wieland WF, Denzinger S, Otto W , Aziz A, Fritsche HM, Gierth M. The Charlson Comorbidity Index Predicts Survival after Disease Recurrence in Patients following Radical Cystectomy for Urothelial Carcinoma of the Bladder. Urol Int. 2014;93(3):303-10. Epub 19.08.2014	1,426	Co-Autor
120*	Aziz A, Rink M, Gakis G, Kluth LA, Dechet C, Miller F, Otto W , Gierth M, Denzinger S, Schwentner C, Stenzl A, Fisch M, Burger M, Fritsche HM. Preoperative C-Reactive Protein in the Serum: A Prognostic Biomarker for Upper Urinary Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Urol Int. 2014;93(3):352-60. Epub 19.08.2014	1,426	Co-Autor
119*	Aziz A, Madersbacher S, Otto W , Mayr R, Comploj E, Pycha A, Denzinger S, Fritsche HM, Burger M, Gierth M. Comparative Analysis of Gender-Related Differences in Symptoms and Referral Patterns prior to Initial Diagnosis of Urothelial Carcinoma of the Bladder: A Prospective Cohort Study. Urol Int. 2015;94(1):37-44. Epub 13.08.2014	1,313	Co-Autor
118*	Gakis G, Fritsche HM, Hassan F, Kluth L, Miller F, Soave A, Otto W , Schwentner C, Todenhöfer T, Dahlem R, Burger M, Fisch M, Stenzl A, Aziz A, Rink M. Prognostic relevance of postoperative platelet count in upper tract urothelial carcinoma after radical nephroureterectomy. Eur J Cancer. 2014 Oct;50(15):2583-91. Epub 31.07.2014	5,417	Co-Autor
117	Otto W , Burger M, Denzinger S, Hartmann A. Karzinogenese des Harnblasentumors Urologische Nachrichten 7/2014	-	Erst-Autor
116*	Aziz A, Fritsche HM, Gakis G, Kluth LA, Hassan Fa, Engel O, Dahlem R, Otto W , Gierth M, Denzinger S, Schwentner C, Stenzl A, Shariat SF, Fisch M, Burger M, Rink M. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. Urol Oncol. 2014 Nov;32(8):1141-50. Epub 22.05.2014	2,768	Co-Autor
115	Otto W , Lausenmeyer EM. CME-Artikel Diagnostische und Therapeutische Strategien zum Benignen Prostatasyndrom in Klinik und Praxis Urologie Scan 2/2014	-	Erst-Autor

114*	Gierth M, Aziz A, Fritsche HM, Burger M, Otto W , Zeman F, Pawlik MT, Hansen E, May M, Denzinger S. The effect of intra- and postoperative allogenic blood transfusion on patients' survival undergoing radical cystectomy for urothelial carcinoma of the bladder. World J Urol. 2014 Dec;32(6):1447-53. Epub 08.02.2014	2,666	Co-Autor
113	Otto W , Rubenwolf PC, Bertz S, Denzinger S, Burger M, Hartmann A. Potentielle Prognosemarker des frühinvasiven Harnblasenkarzinoms. Journal Onkologie 2/2014	-	Erst-Autor
112*	Gunia S, Jain A, Albrecht K, Koch S, Otto W , Denzinger S, Götz S, Niessl N, Burger M, May M. Diagnostic and prognostic impact of peritumoral stromal remodeling in patients with surgically treated invasive penile squamous cell cancer. Hum Pathol. 2014 Jun;45(6):1169-76. Epub 31.01.2014	2,769	Co-Autor
111	Kranz J, Kunath F, Borgmann H, Dräger DL, Krabbe LM, Kröger N, Otto W , Spek A, Zengerling F, Wullich B, Miernik A. Mit „UroEvidence“ spielen die deutschen Urologen eine Vorreiterrolle. Journal Onkologie 1/2014	-	Co-Autor
110*	Kranz J, Kunath F, Borgmann H, Dräger DL, Krabbe LM, Kröger N, Otto W , Spek A, Zengerling F, Wullich B, Miernik A. [„UroEvidence“ - Centre for knowledge translation of the DGU (German Society of Urology): Summarizing, analysing and making current knowledge available]. German Urologe A. 2014 Jan;53(1):83-6. Epub 10.12.2013	0,162	Co-Autor
109*	Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W , Denzinger S, Bertz S, Hartmann A, Karl A, Knüchel R, Dahl E. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high grade urothelial tumours. Carcinogenesis. 2014 Mar;35(3):727-36. Epub 21.11.2013	5,333	Co-Autor
108**	Otto W . Kleine Geschichte der Urologie – Schon im Alten Ägypten wurden urogenitale Erkrankungen behandelt. In: Wie wir wurden, was wir sind... Forum Verlag, Regensburg, 2013	-	Einzel-Autor
107**	Otto W . Die „Regensburger Sieben“ – Forschung und Lehre haben hier einen hohen Stellenwert. In: Wie wir wurden, was wir sind... Forum Verlag, Regensburg, 2013	-	Einzel-Autor
106**	Otto W . Prof. Dr. Wolf F. Wieland – Spitzenmediziner aus und für Regensburg. In: Wie wir wurden, was wir sind... Forum Verlag, Regensburg, 2013	-	Einzel-Autor
105*	Becker F, Junker K, Parr M, Hartmann A, Füssel S, Toma M, Grobholz R, Pflugmann T, Wullich B, Strauss A, Behnes CL, Otto W , Stöckle M, Jung V. Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS One. 2013 Oct 22;8(10):e78137 Epub 22.10.2013	3,354	Co-Autor
104*	Rubenwolf PC, Otto W , Denzinger S, Hofstädter F, Wieland WF, Georgopoulos NT. Expression of aquaporin water channels in human urothelial carcinoma: correlation of AQP3 expression with tumour grade and stage. World J Urol. 2014 Aug;32(4):991-7. Epub 11.09.2013	2,666	Co-Autor
103*	Otto W , Denzinger S, Fritsche HM, Burger M, Rößler W, Bertz S, May M, Hartmann A, Hofstädter F, Wieland WF, Eder F. Introduction and First Clinical Application of a Simplified Immunohistochemical Validation System Confirms Prognostic Impact of KI-67 and CK20 for Stage T1 Urothelial Bladder Carcinoma: Single-Center Analysis of Eight Biomarkers in a Series of Three Hundred Six Patients. Clin Genitourin Cancer. 2013 Dec;11(4):537-44. Epub 10.07.2013	1,693	Erst-Autor

102*	Aziz A, Gierth M, Fritsche HM, May M, Otto W , Denzinger S, Wieland WF, Merseburger A, Riedmiller H, Kocot A, Burger M. Oncological Outcome of Primary versus Secondary Muscle-Invasive Bladder Cancer Is Comparable after Radical Cystectomy. Urol Int. 2013;91(1):97-102. Epub 06.06.2013	1,151	Co-Autor
101*	Gierth M, Fritsche HM, Buchner H, May M, Aziz A, Otto W , Bolenz C, Trojan L, Hermann E, Tiemann A, Müller SC, Ellinger J, Brookman-May S, Stief CG, Tilki D, Nuhn P, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Wieland WF, Riedmiller H, Denzinger S, Bastian PJ, Burger M. Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. World J Urol. 2014 Apr;32(2):365-71. Epub 05.06.2013	2,666	Co-Autor
100	Otto W , Denzinger S, Fritsche HM, Rößler W, Wieland WF, Burger M, Rubenwolf PC. Expressionsverlust von Aquaporin 3 als immunhistochemischer Prognose-faktor für das progressionsfreie Überleben von Patienten mit pT1 urotheliale Harnblasenkarzinom Urologische Nachrichten 3/2013 (kein IF)	-	Erst-Autor
99*	May M, Burger M, Otto W , Hakenberg OW, Wieland WF, May D, Hofstädter F, Götz S, Niessl N, Fritsche HM, Birnkammer K, Gilfrich C, Peter J, Jain A, Koch S, Lebentrau S, Riedmiller H, Rössler W, Denzinger S, Brookman-May S, Gunia S. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis. BJU Int. 2013 Aug;112(4):E383-90. Epub 10.01.2013	3,130	Co-Autor
98**	Otto W , Rößler W, Primus G. Indikationsstellung zur Neuromodulation bei entzündlichen und degenerativen Erkrankungen des ZNS. In: Neuromodulative Verfahren in Urologie und Proktologie. Unimed Verlag 2013.	-	Erst-Autor
97**	Denzinger S, Otto W , Rößler W. Stellenwert und Leitlinien zur sakralen Neuromodulation bei idiopathischem "overactive bladder" (OAB)-Syndrom. In: Neuromodulative Verfahren in Urologie und Proktologie. Unimed Verlag 2013.	-	Co-Autor
96	Aziz A, Herbst EM, Nowrotek A, Otto W , Brunner J, Gerber P, Wieland WF, Rößler W, Denzinger S. Die Argus-Schlinge ist schnell erlernbar Uro-Forum 12/2012	-	Co-Autor
95*	Otto W , May M, Fritsche HM, Dragun D, Aziz A, Gierth M, Trojan L, Herrmann E, Moritz R, Ellinger J, Tilki D, Buchner A, Höfner T, Brookman-May S, Nuhn P, Gilfrich C, Roigas J, Zacharias M, Denzinger S, Hohenfellner M, Haferkamp A, Müller SC, Kocot A, Riedmiller H, Wieland WF, Stief CG, Bastian PJ, Burger M. Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large german multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med. 2012 Dec;9(6):481-9. Epub 06.12.2012	1,690	Erst-Autor
94*	Gunia S, Erbersdobler A, Koch S, Otto W , Stabiano S, D Alterio C, Brookman-May S. Protein gene product 9.5 is diagnostically helpful in delineating high-grade renal cell cancer involving the renal medullary/sinus region from invasive urothelial cell carcinoma of the renal pelvis. Hum Pathol. 2014 Jun;45(6):1169-76. Epub 14.11.2012	2,769	Co-Autor

93*	<p>Gunia S, Burger M, Hakenberg OW, May D, Koch S, Jain A, Birnkammer K, Wieland WF, Otto W, Hofstädter F, Fritsche HM, Denzinger S, Gilfrich C, Brookman-May S, May M.</p> <p>Inherent Grading Characteristics of Individual Pathologists Contribute to Clinically and Prognostically Relevant Interobserver Discordance Concerning Broders' Grading of Penile Squamous Cell Carcinomas.</p> <p>Urol Int. 2013;90(2):207-13. Epub 26.10.2012</p>	1,51	Co-Autor
92*	<p>Otto W, Denzinger S, Wieland WF, Hartmann A.</p> <p>First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival</p> <p>World J Urol. 2012 Dec;30(6):875-7. Epub 25.10.2012</p>	2,888	Erst-Autor
91*	<p>Fritsche HM, Aziz A, Eder F, Otto W, Denzinger S, Wieland WF, May M, Hofstädter F, Hartmann A, Burger M.</p> <p>Potentially clinically relevant prostate cancer is found more frequently after complete than after partial histopathological processing of radical cystoprostatectomy specimens.</p> <p>Virchows Arch. 2012 Dec;461(6):655-61. Epub 09.10.2012</p>	2,676	Co-Autor
90*	<p>Otto W*, Rubenwolf PC*, Burger M, Fritsche HM, Rößler W, May M, Hartmann A, Hofstädter F, Wieland WF, Denzinger S</p> <p>Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer</p> <p>BMC Cancer. 2012 Oct 8;12(1):459. Epub 08.10.2012</p>	3,333	Erst-Autor
89*	<p>Fritsche HM, May M, Denzinger S, Otto W, Siegert S, Giedl C, Giedl J, Eder F, Agaimy A, Novotny V, Wirth M, Stief C, Brookman-May S, Hofstädter F, Gierth M, Aziz A, Kocot A, Riedmiller H, Bastian PJ, Toma M, Wieland WF, Hartmann A, Burger M.</p> <p>Prognostic Value of Perinodal Lymphovascular Invasion Following Radical Cystectomy for Lymph Node-positive Urothelial Carcinoma.</p> <p>Eur Urol. 2013 Apr;63(4):739-44. Epub 28.09.2012</p>	13,693	Co-Autor
88*	<p>Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, Shariat SF.</p> <p>Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.</p> <p>World J Urol. 2013 Feb;31(1):5-11. Epub 26.09.2012</p>	3,423	Co-Autor
87*	<p>Brookman-May S, May M, Ficarra V, Kainz MC, Kampel-Kettner K, Kohlschreiber S, Wenzl V, Schneider M, Burger M, Wieland WF, Otto W, Tilki D, Gilfrich C, Hohenfellner M, Pahernik S, Chromecki TF, Stief C, Zigeuner R; Members of the CORONA (Collaborative Research On Renal Neoplasms Association) Project.</p> <p>Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series.</p> <p>World J Urol. 2013 Oct;31(5):1309-16. Epub 19.09.2012</p>	3,423	Co-Autor
86	<p>Rößler W, Otto W.</p> <p>Sakrale Neuromodulation bei irritativen Harnblasensymptomen</p> <p>ÄrzteWoche 9/2012</p>	-	Senior-Autor
85*	<p>Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, Soloway M, Solsona E, Sved P, Babjuk M, Brausi MA, Cheng C, Comperat C, Dinney C, Otto W, Shah J, Thüroff J, Witjes JA.</p> <p>ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder.</p> <p>Eur Urol. 2013 Jan;63(1):36-44. Epub 05.09.2012</p>	13,693	Co-Autor

84**	Burger M, Witjes F, Babjuk M, Brausi M, Cheng C, Comperat E, Dinney C, Jager W, Otto W , Shah J, Thuroff J. High grade Ta, CIS, and T1 urothelial Carcinoma. In: Guidelines on Bladder Cancer, Edition 2012. European Association of Urology & ICUD, Paris, 2012.	-	Co-Autor
83*	Denzinger S, Nowrotek A, Weingart P, Burger M, Wieland WF, Rößler W, Wieland WF, Otto W . Sacral neuromodulation leads to relevant reduction of post-void residual volume and need of intermittent catheterization in patients with non-obstructive urinary retention. Neuromodulation. 2012 Nov-Dec;15(6):586-91; discussion 591. Epub 01.06.2012	1,190	Senior-Autor
82*	Otto W , Nowrotek A, Burger M, Wieland WF, Rößler W, Denzinger S. [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic]. Aktuelle Urol. 2012 May;43(3):162-6. Epub 25.05.2012	0,474	Erst-Autor
81*	Otto W* , Bertz S*, Denzinger S, Wieland WF, Burger M, Stöhr R, Link S, Hofstädter F, Hartmann A. Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer. Eur Urol. 2014 Jan;65(1):218-26. Epub 19.05.2012	13,938	Erst-Autor
80*	Mayr R, May M, Martini T, Lodde M, Comploj E, Pycha A, Strobel J, Denzinger S, Otto W , Wieland W, Burger M, Fritsche HM. Comorbidity and Performance Indices as Predictors of Cancer-Independent Mortality But Not of Cancer-Specific Mortality After Radical Cystectomy for Urothelial Carcinoma of the Bladder. Eur Urol. 2012 Oct;62(4):662-70. Epub 12.04.2012	12,480	Co-Autor
79**	Rößler W, Otto W . Therapie der weiblichen Belastungsharninkontinenz mittels BARD® ALIGN® TO transobturatorischem Harnröhrenstützsystem. In: Implantate in der Inkontinenz- und Prolaps-Chirurgie. Akademischer Verlag München; 2012	-	Senior-Autor
78*	Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo da Pozzo L, Bertini R, Ficarra V, Otto W , Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, Shariat SF. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. BJU Int. 2012 Sep;110(5):674-81. Epub 20.02.2012	3,046	Co-Autor
77*	Walter B, Hartmann A, Hofstädter F, Junker K, Moch H, Bertz S, Denzinger S, Otto W , Gajda M, Stoehr CG. Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria. Virchows Arch. 2012 Mar;460(3):343-52. Epub 17.02.2012	2,676	Co-Autor
76*	May M, Bastian PJ, Brookman-May S, Fritsche HM, Bolenz C, Gilfrich C, Otto W , Trojan L, Herrmann E, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M. External Validation of a Risk Model to Predict Recurrence-Free Survival After Radical Cystectomy in Patients With Pathological Tumor Stage T3N0 Urothelial Carcinoma of the Bladder. J Urol. 2012 Apr;187(4):1210-4. Epub 14.02.2012	4,020	Co-Autor

75*	Mayr R, May M, Martini T, Lodde M, Pycha A, Comploj E, Wieland WF, Denzinger S, Otto W , Burger M, Fritsche HM. Predictive Capacity of Four Comorbidity Indices Estimating perioperative Mortality after Radical Cystectomy for Urothelial Carcinoma of the Bladder. BJU Int. 2012 Sep;110(6 Pt B):E222-7. Epub 07.02.2012	3,046	Co-Autor
74	Otto W , Denzinger S. Paravasation als Notfallkomplikation intravasaler Chemotherapien Journal Onkologie 1/2012	-	Erst-Autor
73	Otto W , Nowrotek A, Burger M, Weingart P, Wieland WF, Rößler W, Denzinger S. Sakrale Neuromodulation vielversprechend in der Zweitlinien-Behandlung von Harnblasen-funktionsstörungen Urologische Nachrichten 1/2012	-	Erst-Autor
72*	Burger M, Otto W , Hartmann A. Re: Bas W.G. van Rhijn, Theo H. van der Kwast, Sultan S. Alkhateeb, et al. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol 2012;61:378-84 Eur Urol. 2012 Apr;61(4):e31-2; author reply e33-4. Epub 11.01.2012	10,476	Co-Autor
71*	Rubenwolf PC, Denzinger S, Otto W . Aquaporin 3 protein expression in transitional cell carcinoma: a potential marker with regard to tumour progression and prognosis? Eur Urol. 2012 Mar;61(3):627-8. Epub 21.12.2011	10,476	Senior-Autor
70*	Stoehr CG, Stoehr R, Hartmann A, Hofstaedter F, Junker K, Blaszyk H, Wieland WF, Otto W , Denzinger S, Walter B. Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma. J Cancer Res Clin Oncol. 2012 Feb;138(2):359-61. Epub 28.11.2011	2,914	Co-Autor
69	Otto W , Fritsche HM, Burger M, Rößler W, Wieland WF, Denzinger S. Prognoseparameter des frühinvasiven Harnblasenkarzinoms Journal Onkologie 11/2011	-	Erst-Autor
68	Bründl J, Denzinger S, Wieland WF, Otto W . Update EAU-Guidelines 2011 beim muskelinvasiven und metastasierten Urothelkarzinom der Harnblase Journal Onkologie 11/2011	-	Senior-Autor
67*	May M, Bastian PJ, Brookman-May S, Fritsche HM, Tilki D, Otto W , Bolenz C, Gilfrich C, Trojan L, Herrmann E, Moritz R, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Wieland WF, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol Oncol. 2013 Oct;31(7):1141-7. Epub 06.11.2011	3,363	Co-Autor
66*	Denzinger S, Bertz S, Otto W , Wieland WF, Stoehr R, Hofstaedter F, Hartmann A. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology. 2011 Oct;59(4):722-32. Epub 20.10.2011	3,082	Co-Autor
65*	May M, Stief CG, Brookman-May S, Otto W , Gilfrich C, Roigas J, Zacharias M, Wieland WF, Fritsche HM, Hofstädter F, Burger M. Gender dependent cancer-specific survival following radical cystectomy. World J Urol. 2012 Oct;30(5):707-13. Epub 9.10.2011	2,888	Co-Autor
64*	Otto W , Gerber P, Rößler W, Wieland WF, Denzinger S. Predictive value of positive surgical margins after radical prostatectomy for lymph node metastasis in locally advanced prostate carcinoma Adv Urol. 2012;2012:618574. Epub 03.10.2011	1,64	Erst-Autor

63*	Otto W , Burger M, Fritsche HM, Rößler W, Wieland WF, Denzinger S. The enlightenment of bladder cancer treatment: origin and progress of photodynamic diagnosis. Review Future Oncol. 2011 Sep;7(9):1057-66. Review. Epub 15.09.2011	3,163	Erst-Autor
62	Gierth M, Denzinger S, Wieland WF, Burger M, Fritsche HM, Otto W . Nierenteilresektion – Vergleich der offenen und laparoskopischen Technik Journal Onkologie 9/2011	-	Senior-Autor
61	Otto W , Nowrotek A, Burger M, Wieland WF, Roessler W, Denzinger S. Aktuelle Diagnostik und Therapie der überaktiven Harnblase Journal Med 9/2011	-	Erst-Autor
60*	Schneider S, Popp D, Denzinger S, Otto W . Hydronephrosis by an ureteral filia as a rare location of prostate carcinoma metastazation: a case report Adv Urol. 2012;2012:656023. Epub 07.09.2011	1,64	Senior-Autor
59*	Fritsche HM, Eder F, Otto W , Hofstaedter F, Denzinger S, Burger M, Wieland WF. Waterjet aided transurethral dissection of Urothelial Carcinoma: a prospective clinical study. J Endourol. 2011 Oct;25(10):1599-603. (IF 2011: 1,847) Epub 04.08.2011	1,847	Co-Autor
58*	May M, Bastian PJ, Burger M, Brookman-May S, Bolenz C, Trojan P, Herrmann E, Michel MS, Wülfing C, Tiemann A, Müller SC, Ellinger J, Buchner A, Wieland WF, Stief CG, Tilki D, Otto W , Gilfrich C, Höfner T, Hohenfellner M, Haferkamp K, Roigas J, Zacharias M, Denzinger S, Gunia S, Fritsche HM. Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder. BJU Int. 2011 Oct;108(8 Pt 2):E278-83. Epub 23.06.2011	2,844	Co-Autor
57*	May M, Fritsche HM, Brookman-May S, Burger M, Otto W , Bolenz C, Trojan L, Herrmann E, Michel MS, Wülfing C, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Müller O, Bretschneider-Ehrenberg P, Zacharias M, Gunia M, Patrick PJ. [Influence of older age on survival after radical cystectomy due to urothelial carcinoma of the bladder: survival analysis of a German multicentre study after curative treatment of urothelial carcinoma of the bladder]. Urologe A. 2011 Jul;50(7):821-9. German. Epub 06.05.2011	0,497	Co-Autor
56*	May M, Burger M, Brookman-May S, Otto W , Peter J, Rud O, Fritsche HM, Bolenz C, Trojan L, Herrmann E, Michel MS, Wülfing C, Moritz R, Tiemann A, Müller CS, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Bretschneider-Ehrenberg P, Müller O, Zacharias M, Gunia S und Bastian PJ. [Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumour stages before surgery?]. Urologe A. 2011 Jun;50(6):706-13. German. Epub 14.04.2011	0,497	Co-Autor
55*	Otto W , Shariat SF, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Artibani W, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Burger M, Karakiewicz PI, Ficarra V, Novara G. Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicentre analysis of 772 patients. World J Urol. 2011 Aug;29(4):487-94. Epub 20.02.2011	2,411	Erst-Autor

54*	Otto W , Fritsche HM, Wild PJ, Wieland WF, Hartmann A, Burger M, Hofstädter F, Denzinger S. Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder. Path Res Pract 2011;207(3):161-3. Epub 17.01.2011	1,213	Erst-Autor
53	Otto W. Die jugendlichen Siebziger – keine Angst vor der Neoblase! Die Bedeutung des Lebensalters für Therapie und Prognose des Harnblasenkarzinoms. You are Urology 2011; 2 (2)	-	Einzel-Autor
52	Otto W , Nowrotek A, Denzinger S, Rößler W. Sakrale Neuromodulation: neue Hoffnung für Patienten mit Therapie refraktären Blasenfunktionsstörungen. Urologische Nachrichten 11/2010	-	Erst-Autor
51*	Seitz C, Gupta A, Shariat SF, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Otto W , Tritschler S, Bastian PJ, Carballido J, Ficarra V, Karakiewicz PI, Artibani W, Mazzoleni G, Novara G. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J Urol. 2010 Nov;184(5):1895-900. Epub 17.10.2010	4,016	Co-Autor
50*	Otto W , Mankertz A, Santibanez S, Saygili H, Wenzel J, Jilg W, Wieland WF, Borgmann S. Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August-October 2010. Euro Surveill. 2010;15(50):pii=19748. Epub 16.10.2010	6,15	Erst-Autor
49*	Kreiner B, Denzinger S, Ganzer R, Fritsche HM, Burger M, Wieland WF, Otto W. Neuroendocrine carcinoma of the seminal vesicles presenting with Lambert Eaton syndrome: a case report. J Med Case Reports. 2010 Oct 12;4(1):320. Epub 12.10.2010	0,64	Senior-Autor
48*	Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W , Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, Shariat SF. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol. 2012 Sep;30(5):666-72. Epub 08.10.2010	3,647	Co-Autor
47*	Shariat SF, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W , Karakiewicz PI, Ficarra V, Novara G. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2011 Aug;29(4):481-6. Epub 01.10.2010	2,411	Co-Autor
46*	Otto W , Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, Hartmann A, Bertz S. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011;107(3):404-8. Epub 12.08.2010	2,844	Erst-Autor
45	Otto W , Denzinger S, Burger M, Rößler W, Wieland WF. Zytoreduktive Therapie als neuer Behandlungsansatz bei fortgeschrittenem Prostatakarzinom: Fallvorstellung und Einordnung der Methode. Journal Onkologie 10/2010	-	Erst-Autor

44	Lotter G, Denzinger S, Ganzer R, Wieland WF, Otto W . Systemische Therapieoptionen beim Prostatakarzinom – welche Möglichkeiten bestehen nach dem Einsatz von Docetaxel? Journal Onkologie 10/2010	-	Senior-Autor
43	Otto W , Gierth M, Nowrotek A, Denzinger S, Burger M, Rößler W, Wieland WF. So sollte es "ablaufen" - Epidemiologie, Ätiologie, Diagnostik und Therapie des Benigen Prostatasyndroms. Journal Med 8/2010	-	Erst-Autor
42*	Otto W , Denzinger S, Fritsche HM, Burger M, Wieland WF, Hofstädter F, Hartmann A, Bertz S. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011;107(3):404-8. Epub 12.08.2010	2,844	Erst-Autor
41*	Otto W , Fritsche HM, Dirmeyer M, Burger M, Straub M, Rössler W, Wieland WF, Denzinger S. [Analysis of Clinical, Histopathological and Follow-Up Data on Transurethral Resections of the Bladder Performed during One Year at a University Centre] Aktuelle Urol. 2010 Sep;41(5):316-9. German. Epub 28.07.2010	0,303	Erst-Autor
40*	Fritsche HM, Burger M, Dietmaier W, Denzinger S, Bach E, Otto W , Doblinger M, Schwarz S, Buchner H, Hartmann A. Multicolor FISH (UroVysion) facilitates follow-up of patients with high-grade urothelial carcinoma of the bladder. Am J Clin Pathol. 2010 Oct;134(4):597-603. Epub 10.01.2010	2,463	Co-Autor
39*	Herrmann E, Trojan L, Becker F, Wülfing C, Schrader AJ, Barth P, Stöckle M, Hammerschmied CG, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Legal W, Wullich B, Bolenz C, Klein T, Noldus J, Bierer S, Hertle L, Brenner W, Roos F, Michel MS, Walter B, Wieland W, Gerss J, Otto W , Hartmann A. Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review. J Urol. 2010;183(2):460-6. Epub 14.12.2009	4,016	Co-Autor
38*	Zaak D, Burger M, Otto W , Bastian PJ, Denzinger S, Stief CG, Buchner H, Hartmann A, Wieland WF, Shariat SF, Fritsche HM. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int. 2010 Aug;106(3):342-8. Epub 11.12.2009	3,19	Co-Autor
37*	Otto W , Fritsche HM, Burger M, Rößler W, Wieland WF, Denzinger S. Photodynamische Diagnostik des pTa/pT1/pTis-Harnblasenkarzinoms: eine onkologische Bilanz nach 100 Monaten. J Urol Urogynäkol, 2009;16(2):35-39	-	Erst-Autor
36*	Burger M, Stief CG, Zaak D, Stenzl A, Wieland WF, Jocham D, Otto W , Denzinger S. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology. 2009 Dec;74(6):1282-6. Epub 12.10.2009	2,365	Co-Autor
35	Borchardt A, Lotter G, Ganzer R, Denzinger S, Otto W . Systemische Therapie fortgeschrittener urogenitaler Tumorerkrankungen, Teil 3: Peniskarzinom. Journal Onkologie 9/2009	-	Senior-Autor
34	Ganzer R, Otto W , Lotter G, Borchardt A, Denzinger S. Systemische Therapie fortgeschrittener urogenitaler Krebserkrankungen, Teil 4: Hodentumoren. Journal Onkologie 9/2009	-	Co-Autor

33	Otto W , Lotter G, Ganzer R, Borchardt A, Denzinger S. Systemische Therapie fortgeschrittener urogenitaler Krebserkrankungen, Teil 5: Nierenzellkarzinom. Journal Onkologie 9/2009	-	Erst-Autor
32*	Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W , Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. Eur Urol. 2010 Feb;57(2):300-9. Epub 12.09.2009	8,843	Co-Autor
31*	Denzinger S, Burger M, Fritsche HM, Bertz S, Hofstädter F, Wieland WF, Hartmann A, Otto W . Prognostic value of histopathological tumor growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol 2009;43(4):282-87. Epub 09.09.2009	0,99	Senior- Autor
30*	Otto W , Hübner I, Burger M, Rößler W, Wieland WF, Denzinger S. [Does Technical Progress mean Clinical Advantage? Analysis of Clinical and Histopathological Parameters of Renal Cell Carcinomas in Long-Term Course.] Aktuell Urol 2009;40(5):303-6. German. Epub 07.08.2009	0,206	Erst-Autor
29	Kreiner B, Siebert T, Fritsche HM, Rößler W, Wieland WF, Otto W . Von der Frühzeit bis in die Hightech-Ära: Steinbehandlung gestern und heute. Journal Med 6/2009	-	Senior- Autor
28*	Otto W , Denzinger S, Bertz S, Gaumann A, Wild PJ, Hartmann A; Stoehr R. No mutations of FGFR3 in adjacent normal urothelium of patients with urothelial carcinoma of the bladder harbouring activating FGFR3 mutations. Int J Cancer 2009;125(9):2205-08. Epub 28.05.2009	4,722	Erst-Autor
27	Otto W , Denzinger S, Burger M, Rößler W, Wieland WF. Von der Allerweltskolik zum komplexen Polytrauma: Diagnostik und Therapie von Notfallerkankungen des Harntrakts. Journal Med 5/2009	-	Erst-Autor
26	Otto W , Ganzer R, Lotter G, Denzinger S, Borchardt A. Systemische Therapie fortgeschrittener urogenitaler Krebserkrankungen, Teil 2: Prostatakarzinom. Journal Onkologie 4/2009	-	Erst-Autor
25*	Otto W , Burger M, Fritsche HM, Blana A, Roessler W, Knuechel R, Wieland WF, Denzinger S. Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? Clinical Medicine: Oncology, 2009;3:53-58. Epub 30.04.2009	0,48	Erst-Autor
24*	Al Meshaan MK, Nayef M, Kwaider T, Otto W , Katchy KC. Peripheral primitive neuroectodermal tumor of the urinary bladder in an Arab woman with history of squamous cell carcinoma: a case report. J Medical Case Reports, 2009; 3:6480. Epub 29.04.2009	0,70	Co-Autor
23	Otto W , Ganzer R, Lotter G, Denzinger S, Borchardt A. Systemische Therapie fortgeschrittener urogenitaler Krebserkrankungen, Teil 1: Harnblasenkarzinom. Journal Onkologie 2/2009	-	Erst-Autor
22	Otto W . Neuer Prognosefaktor des pT1G3 Harnblasenkarzinoms? Urologische Nachrichten 9/2008	-	Einzel-Autor

21	Otto W. Wachstumsmuster an der Tumorinvasionsfront als Prognoseparameter des pT1G3-Harnblasenkarzinoms. MedReport 9/2008	-	Einzel-Autor
20	Otto W. Therapie des pT1G3 Harnblasenkarzinoms - neue Entscheidungshilfe aus dem histopathologischen Befund? ⌘ Current Congress 9/2008	-	Einzel-Autor
19	Fritsche HM, Otto W. „Active Surveillance“: Aktive Überwachung des Prostatakarzinoms. Journal Onkologie 8/2008	-	Senior-Autor
18	Otto W , Fritsche HM, Denzinger S, Burger M, Rößler W, Wieland WF. Urologische Komplikationen nach gynäkologischen Tumoroperationen und deren Behandlung. Journal Onkologie 8/2008	-	Erst-Autor
17	Fritsche HM, Burger M, Denzinger S, Otto W. Neues aus Diagnostik und Therapie des Harnblasenkarzinoms: Was Sie wahrscheinlich noch nicht wissen. Journal Onkologie 8/2008	-	Senior-Autor
16*	Fritsche HM, Burger M, Ganzer R, Otto W , Denzinger S, Wieland WF. [Impact of comorbidity on perioperative mortality after radical cystectomy]. Aktuelle Urol. 2008 May;39(3):225-8. Epub 12.03.2008	0,168	Co-Autor
15**	Denzinger S, Otto W. Einleuchtender Fortschritt: Fluoreszenzdiagnostik in der Blasenkrebs-Behandlung. Blick in die Wissenschaft, 2008;17:36-42.	-	Senior-Autor
14*	Denzinger S, Wieland WF, Otto W. [Modern Diagnosis of Bladder Cancer]. MMW Fortschr Med. 2008 Jan 31;150(5):36-39. Epub 31.01.2008	0,04	Senior-Autor
13*	Denzinger S, Burger M, Fritsche HM, Ganzer R, Blana A, Wieland WF, Otto W. [Bladder Preservation or Initial Cystectomy in T1G3 Bladder Cancer: Which Parameters Help in Therapeutic Decision-Making?] Aktuelle Urol. 2008 Jan;39(1):58-61. Epub 28.11.2007	0,168	Senior-Autor
12*	Denzinger S, Wieland WF, Otto W , Filbeck T, Knuechel R, Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int. 2008 Mar;101(5):566-9. Epub 05.11.2007	2,704	Co-Autor
11	Denzinger S, Rößler W, Wieland WF, Otto W. Photodynamische Diagnostik oberflächlicher Harnblasentumoren - "Einleuchtende" Rezidivprophylaxe des Harnblasenkarzinoms. Uro News, 2007;11:47-50.	-	Senior-Autor
10*	Denzinger S, Otto W , Fritsche HM, Roessler W, Wieland WF, Hartmann A, Burger M. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol. 2007 Nov;14(11):995-9; discussion 999. Epub 18.10.2007	0,769	Co-Autor
9*	Denzinger S, Rössler W, Otto W. [Photodynamic diagnostic of superficial bladder carcinoma]. Dtsch Med Wochenschr. 2007 Nov;132(44):2332-5. German. Epub 18.10.2007	0,433	Senior-Autor
8**	Otto W , Denzinger S. Theorie und Praxis der urologischen Endoskopie. Begleitschrift zur Lehrveranstaltung der Klinik und Poliklinik für Urologie der Universität Regensburg. Klinik und Poliklinik für Urologie der Universität Regensburg. Forum Verlag, Regensburg, 2007	-	Erst-Autor

7*	Denzinger S, Wieland WF, Burger M, Otto W . Spontaneous ventral urethral fistula in a young diabetic man: a case report. J Med Case Reports. 2007 Sep 5;1:80. Epub 05.09.2007	-	Senior-Autor
6*	Denzinger S, Fritsche HM, Otto W , Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. 2008 Jan;53(1):146-52. Epub 27.07.2007	6,512	Co-Autor
5	Otto W , Ganzer R, Denzinger S, Fritsche HM. Spontanruptur eines außergewöhnlich großen Adenoms der Nebennierenrinde. Journal Onkologie 7/2007	-	Erst-Autor
4	Denzinger S, Otto W , Rößler W, Wieland WF, Burger M. Fluoreszenzdiagnostik des Harnblasenkarzinoms. Journal Onkologie 7/2007	-	Co-Autor
3*	Denzinger S, Watzlawek E, Burger M, Wieland WF, Otto W . Giant scrotal elephantiasis of inflammatory etiology: a case report. J Med Case Reports. 2007 Jun 2;1(1):23. Epub 02.06.2007	-	Senior-Autor
2*	Denzinger S, Luebke L, Burger M, Kessler S, Wieland WF, Otto W . Vacuum-assisted closure therapy in ureteroileal anastomotic leakage after surgical therapy of bladder cancer. World J Surg Oncol. 2007 Apr 12;5:41. Epub 12.04.2007	-	Senior-Autor
1*	Denzinger S, Otto W , Burger M, Hammerschmied C, Junker K, Hartmann A, Wieland WF, Walter B. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J Surg Oncol. 2007 Feb 5;5:16. Epub 05.02.2007	-	Co-Autor